Characteristics of the IgAN cohort in this study.

Data are presented as mean ± SEM or median (inter-quartile range [IQR]) for continuous variables and proportions for categorical variables. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial blood pressure; UP: Urinary protein; PCr: Plasma creatinine; TC: Total cholesterol; TG: Triglyceride; UUMOD: Urinary uromodulin; TA-MAP: Time-average blood pressure; TA-proteinuria: Time-average proteinuria. ESKD: End stage kidney disease. ACEi: Angiotensin I Converting Enzyme Inhibitor. ARB: Angiotensin receptor blocker. CTX: Cyclophosphamide. 100% of follow-up patients (N = 185) accepted ACEi and/or ARB therapy. 42% of patients accepted steroid and/or cyclophosphamide. eGFR was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [15]. eGFR decline rate: was obtained by fitting a straight line through the calculated eGFR using linear regression and the principal of least squares for every patient [13]. N1: the whole cohort; N2: the subgroup with follow-up; N3: the subgroup without follow-up data.